← All trials
NCT05666700
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Aug 31, 2025
- Completion date
- Aug 31, 2025
- First posted
- Dec 28, 2022
- Last posted
- Dec 28, 2022
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peter MacCallum Cancer CentreLead sponsor
- Janssen Pharmaceutica NVCollaborator
- Peter MacCallum Cancer CentreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.